India’s pharmaceutical exports climbed to $30.5 billion in FY2025, reflecting a 9.3% year-on-year growth, according to a new report by Rubix Data Sciences. The momentum is expected to continue, with projections indicating pharma exports could double to $65 billion by 2030.
This surge comes despite mounting global headwinds, notably potential US tariffs and supply chain dependencies on China. Indian companies are pushing ahead with complex generics, strategic global acquisitions, and regulatory fortification to stay competitive.
Highlights from the Rubix Report:
- Growth Drivers:
- Rising demand for complex generics
- Expansion into developed markets (US, Europe)
- Focus on regulatory compliance and US-oriented manufacturing
- Challenges Ahead:
- The US accounts for over 32% of India’s pharma exports.
- A potential 200% tariff by the US threatens export stability.
- 74% of India’s bulk drug imports still come from China—posing strategic risk.
- Strategic Moves by Indian Pharma:
- Investment in US/EU-based manufacturing and CDMO acquisitions
- Entry into advanced therapeutic areas (oncology, anti-diabetics, CNS)
- Targeting opportunities from upcoming global patent expiries
- Expert Insight:
“From navigating tariff pressures to strengthening compliance and expanding globally, the sector is showing clear signs of strategic maturity.”
— Mohan Ramaswamy, Co-founder & CEO, Rubix Data Sciences
- Looking Ahead:
- Firms are diversifying supply chains and customer bases
- Building resilience to withstand policy shifts and geopolitical tensions
- Awaiting critical tariff decisions by August 1, which could reshape global pharma flows
This performance reflects not just growth, but the strategic recalibration of Indian pharma amid global volatility. The sector’s agility and focus on innovation are paving the way for long-term global leadership.
